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Associations between dietary intake of various fats and
specific K-ras mutations in colorectal cancer (CRC) were
investigated within the framework of The Netherlands
Cohort Study on diet and cancer (NLCS). After 7.3 years
of follow-up and with exclusion of the first 2.3 years, 448
colon and 160 rectal cancer patients and 2948 subcohort
members (55--69 years at baseline) were available for data-
analyses. Mutation analysis of the K-ras gene was per-
formed on all archival colon and rectal adenocarcinoma
specimens. Case-cohort analyses were used to compute
adjusted incidence rate ratios (RR) and 95% confidence
intervals (CI) for colon and rectal cancer cases and for
K-ras mutation subgroups. The intake of total, saturated
and monounsaturated fat was not significantly associated
with colon or rectal cancer. High intake of dietary poly-
unsaturated fat and, specifically, linoleic acid is associated
with an increased risk of mutated K-ras colon tumours. The
RRs for 1 SD of increase of polyunsaturated fat and linoleic
acid were 1.21 (95% CI 1.05--1.41) and 1.22 (95% CI
1.05--1.42), respectively, and similar associations were
observed for both G4A transitions and G4T or G4C
transversions in the colon. In contrast, no significant asso-
ciations were observed with rectal cancer risk, overall nor
with specific K-ras mutation status. A high intake of poly-
unsaturated fat, in particular linoleic acid, may be an
important dietary risk factor for K-ras mutated colon
tumours, possibly by generating G4A transitions or
G4T or G4C transversions in the K-ras oncogene.
Introduction
The current epidemiological evidence for the association of
total fat and specific fatty acids with colorectal cancer (CRC)
risk is controversial (1,2). The observed inconsistencies could,
in part, be due to the heterogeneity of the colon and rectal
cancer endpoint that is studied. Associations may become
more apparent when the molecular events involved in colo-
rectal carcinogenesis are taken into account.
The majority of colon and rectal tumours develop from small
adenomatous polyps through a well-defined sequence of cyto-
logical and morphological changes (3), a process that is asso-
ciated with the acquisition of somatic mutations (4,5). A
genetic alteration that occurs in adenomas (10%) as well as
carcinomas (40%) in colon and rectal cancer is the oncogenic
activation of the K-ras gene by mutations. Activating muta-
tions are mainly found in codons 12 and 13 (4,6--8). The most
frequently observed types of point mutations are G4A trans-
itions (8,9), and G4T and G4C transversions (10).
The link between fat intake and the pattern of mutations in
human colon and rectal cancer is not clear. Only a few epide-
miological studies have been conducted up to date on the
association between the intake of fat and K-ras mutation status
(11--14) and results are inconsistent. Experimental studies
suggest that peroxidation of v-6 polyunsaturated fatty acids
(PUFAs) could lead to the accumulation of by-products like
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE).
These compounds could react with DNA to form adducts,
mainly the pyrimidopurinone adduct of deoxyguanosine
(M1G) (15--17). The presence of the M1G adducts resulted
predominantly in G4A and G4T, with very few G4C trans-
versions in bacteria (16,18,19).
Consequently, exposures to specific dietary fat and fatty
acids could contribute to the heterogeneity of acquired genetic
alterations in the K-ras oncogene observed in colon and rectal
tumours. Associations between dietary intakes of fat and spe-
cific fatty acids and the risk of specific point mutations in the
K-ras oncogene in patients with colon and rectal cancer were
studied within the framework of The Netherlands Cohort
Study on diet and cancer (NLCS).
Materials and methods
Study population
The participants in this study are incident, colon and rectal cancer cases
and subcohort members from the NLCS, which has been described in detail
elsewhere (20). Briefly, the study was initiated in 1986 and includes 58 279
men and 62 573 women, aged 55--69 years old at baseline, who originated from
204 Dutch municipalities with computerized population registries. A self-
administered questionnaire on diet and other risk factors for cancer was
completed at baseline. The entire cohort is being monitored for cancer occur-
rence by annual record linkage to the Netherlands Cancer Registry (NCR, nine
cancer registries in The Netherlands) and to PALGA, a nationwide network
and registry of histo- and cytopathology (www.palga.nl) (21). In the munici-
palities included in the NLCS, the NCR and PALGA, together, have nearly
100% coverage since the start of the study (22--25). PALGA also provides
necessary information on the identification of the pathology laboratory loca-
tion of the storage of paraffin-embedded blocks of the eligible CRC patients.
Accumulation of person-time in the cohort has been estimated through biennial
vital status follow-up of a subcohort of 3500 men and women who were
randomly selected after baseline exposure measurement (21). Cases with
prevalent cancer other than non-melanoma skin cancer were excluded from
the subcohort, which left 3346 men and women for analysis.
Abbreviations: CI, confidence intervals; CRC, colorectal cancer; MDA,
malondialdehyde; M1G, pyrimidopurinone--deoxyguanosine adducts; MUFA,
monounsaturated fat; NLCS, The Netherlands Cohort Study; RR, rate ratios;
PUFA, polyunsaturated fat.
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The first 2.3 years of follow up were excluded due to incomplete coverage
of PALGA alone in some of the municipalities included in the NLCS. Within
this period, 83 subcohort members were either deceased or diagnosed with
cancer other than non-melanoma skin cancer, leaving 3263 men and women
for analysis. From 1989 until 1994, 929 incident cases with histologically
confirmed CRC were observed of whom 819 could also be linked to a
PALGA report of the lesion. The PALGA database was used to identify and
locate tumour tissue in Dutch pathology laboratories. CRC was classified
according to site as follows: colon, i.e. cecum through sigmoid colon (ICD-
O-1 codes: 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8,
153.9), rectosigmoid (ICD-O-1 code 154.0) and rectum (ICD-O-1 code
154.1). Information about age at baseline, sex and family history of CRC (at
baseline) was retrieved from the NLCS database.
Tissue samples
This study is based on data of gene mutation analysis from CRC patients,
described in detail elsewhere (8). Briefly, tumour material of all CRC patients
was collected after approval by the Medical Ethics Committees of Maastricht
University, the NCR and PALGA. Subsequently, all pathology laboratories in
The Netherlands agreed to make relevant tissue samples available upon request
from PALGA. Tissue samples of the 819 cases were distributed among 54
pathology laboratories throughout The Netherlands. Tumour tissue specimen
collection started in August 1999 and was completed in December 2001. The
loss to follow-up of tissue samples of cases amounted to 5%. Tissue samples
from nine patients registered in one pathology laboratory could not be retrieved
due to administrative inconsistencies, leaving 810 tissue samples for collec-
tion. For 34 cases, paraffin-embedded material was not available in the
archives of pathology laboratories, leaving 776 cases for the determination of
the K-ras mutation status. For 39 cases (5%), the K-ras mutation status could
not be determined, i.e. for 20 cases only normal colonic mucosa was available,
10 cases were revised with a benign adenoma instead of an adenocarcinoma,
for six cases the yield of DNA was not sufficient enough to determine K-ras
mutation status and for three cases the available tissue did not include malig-
nant CRC tissue. Finally, tumour material from 737 incident colorectal ade-
nocarcinoma cases was available of whom 476 were colon cancer cases, 85
were rectosigmoid cancer cases and 176 were rectal cancer cases. Statistical
analyses were performed separately for colon and rectal cancer as differences
in the aetiology of colon and rectal cancer have been reported (1). Since the
rectosigmoid can be considered as a clinically applied term rather than an
anatomically defined transitional zone between the colon and rectum, patients
with a rectosigmoid tumour were excluded from data analyses. Moreover, the
number of patients with a rectosigmoid tumour was too small for adequate
stratified analyses (8).
Detection of K-ras mutations
Mutation analysis of the exon 1 fragment of the K-ras oncogene, spanning
codons 8--29, was performed on archival colorectal adenocarcinoma specimens
of all 737 CRC patients using macrodissection, nested polymerase chain
reaction (PCR) and direct sequencing of purified fragments, which has been
described in detail elsewhere (8). The method of mutation detection was
validated by the confirmation of reported K-ras status in CRC cell lines and
a good correlation between fresh-frozen and routinely fixed, paraffin-
embedded tissue. The detection limit was 5% mutated DNA. Duplo analyses
revealed a good reproducibility (88%) (8). Evaluation of mutation analysis and
data entry was independently performed by two observers (G.R. and M.L.).
The food frequency questionnaire
The dietary section of the questionnaire was a 150-item semi-quantitative food
frequency questionnaire, which concentrated on habitual consumption of food
and beverages during the year preceding the start of the study. Daily mean
nutrient intakes were calculated using the computerized Dutch food composi-
tion table (26), by cumulating the multiplied frequencies and portion sizes of
all food items with their tabulated nutrient contents. The questionnaire was
validated against a 9-day diet record (27). Crude and energy-gender-adjusted
(in parentheses) correlation coefficients were 0.72 (0.52) for total fat, 0.73
(0.58) for saturated fat and 0.73 (0.75) for PUFA (27). For energy intake the
correlation coefficient was 0.74. On average, the questionnaire covered 91% of
the record intake explaining part of the underestimation of energy intake from
the questionnaire data (as presented in Table I). Questionnaire data were key-
entered twice and processed for all incident cases in the cohort and for all
subcohort members in a manner blinded with respect to case/subcohort status.
This was done in order to minimize observer bias in coding and interpretation
of the data.
For 257 subjects (28 incident colon adenocarcinoma cases, 16 incident
rectal adenocarcinoma cases and 215 subcohort members, two subcohort
members were also colon or rectal cancer cases), dietary data were incomplete
or inconsistent, and they were excluded from the analyses. These subjects
either (i) left 60 or more (out of 150) questionnaire items blank and ate
fewer than 35 items at least once per month and/or (ii) left one or more item
blocks (groups of items, e.g. beverages) blank. Additional details are given
elsewhere (27). Hence, 608 colon and rectal cancer cases and 3048 subcohort
members were available for data analyses.
Intake of specific fatty acids was based on a food composition database with
specific fatty acids derived from the TRANSFAIR study (28). For this data-
base, the hundred foods that contributed most to fat intake in the Dutch dietary
pattern were sampled and analysed as methyl esters of the fatty acids present in
the foods. In the database, total fat includes triglycerides and other lipids such
as phospholipids and sterols. The percentage of triglycerides in total fat is
assumed to be on average 93%, but varies across food sources. Daily intakes of
total fat (g/day), saturated fat (g/day), monounsaturated fat (MUFA) (g/day),
PUFA (g/day), and linolenic acid (g/day) and linoleic acid (g/day) as main
constituents of PUFA were used as exposure variables. Linolenic and linoleic
acid were used as the most abundant sources of v-3 PUFAs and v-6 PUFAs.
For data-analyses, quartiles of the intake of fat and fatty acids were computed
based on the distribution of subcohort members. Daily intake of dietary fibre
(g/day), alcohol (g/day), fruit (g/day), vegetables (g/day) and total energy
(kcal/day) and age at baseline (years), sex (men/women), Quetelet Index (QI;
kg/m2), physical activity (530 min/day, 30--60 min/day, 60--90 min/day,490
min/day), family history of CRC (yes/no) and smoking status (never/ex/
current) were regarded as potential confounders.
Statistical analysis
The overall frequency of K-ras mutations as well as the type of mutation was
computed for all colon and rectal cancer cases as described elsewhere (8). Fat
intake was adjusted for energy by the residual method (29). Mean values of the
continuous variables age at baseline (years), intake of total fat, saturated fat,
MUFA, PUFA, linolenic acid, linoleic acid, dietary fibre, alcohol, fruit, vege-
tables and total energy and QI were evaluated for subcohort members and
colon and rectal cancer cases with wild-type and mutated K-ras gene. Dis-
tributions in the categorical variables sex, family history of CRC, smoking
status and physical activity were evaluated for subcohort members and colon
and rectal cancer patients with wild-type and mutated K-ras gene. Differences
in mean values of the continuous variables and the distributions in categorical
variables between patients with wild-type and mutated K-ras tumours were
tested with the Student's t-test and x2-test, respectively, using the statistical
software package SPSS (version 9).
Incidence rate ratios (RR) and corresponding 95% confidence intervals (CI)
for colon and rectal cancer cases with wild-type or mutated K-ras gene tumours
were estimated according to intakes of quartiles (with the lower quartile of
intake regarded as the reference group) and of 1 standard deviation (SD) of
increase of intake of total fat, saturated fat, MUFA, PUFA, linolenic acid and
linoleic acid using Cox proportional hazards models with the STATA statis-
tical software package (intercooled STATA, version 7). The total person-years
at risk, estimated from the subcohort, were used in the analyses (27). Standard
errors were estimated using the robust Hubert--White sandwich estimator to
account for additional variance introduced by sampling from the cohort. This
method is equivalent to the variance--covariance estimator as presented by
Barlow (30). The proportional hazards assumption was tested using the scaled
Schoenfeld residuals (31). Using the backwards stepwise procedure, all con-
founders were tested in the overall colon and rectal cancer models separately.
Interactions between fat and specific fatty acid intake and sex were tested for
colon and rectal cancer separately and never found to be statistically signific-
ant. Therefore, results for men and women are presented together. Finally, age
at baseline, sex, family history of CRC, smoking status, QI and the intake of
energy were confounders for either one or both of the models and were there-
fore included as covariates for all models to be tested. Since 100 subcohort
members had missing values for QI, results in the tables will be presented for
2948 subcohort members. For each analysis, trends were evaluated with the
Wald test by fitting ordinal exposure variables (quartiles of intake) as contin-
uous terms.
Results
The overall frequency and spectrum of mutations in the K-ras
gene have been presented in detail elsewhere (8). In brief, a total
of 227 mutations were found in 218 (36%) out of 608 colon and
rectal cancer patients. The most frequently observed mutations
are the G4A transitions (54%), G4T transversions (33%) and
G4C transversions (7%). The observed frequencies of the point
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mutation are similar to the frequencies of the 737 colorectal
cancer cases, including rectosigmoid cancer cases, for whom
K-ras status was determined (8).
Table I shows various types of fat intake and other baseline
characteristics of the study population. Colon and rectal cancer
cases were more often men, were older, more frequently
reported a family history of colorectal cancer and had a higher
daily alcohol intake as compared with the subcohort. Colon
cancer cases with a mutated K-ras tumour were significantly
older, had higher daily intakes of PUFA, linoleic acid, fibres
and vegetables than colon cancer cases with a wild-type K-ras
tumour. There were no statistically significant differences
between colon cancer cases with a wild-type K-ras tumour
and a mutated K-ras tumour in dietary intakes of total fat,
saturated fat, MUFA, linolenic acid and other factors presented
in Table I. Rectal cancer cases with a mutated K-ras tumour
were less frequently men as compared with rectal cancer cases
with a wild-type K-ras tumour. No statistically significant
differences between rectal cancer cases with mutated K-ras
tumours and wild-type K-ras tumours were observed for total
fat, specific fatty acids and other (dietary) factors.
Associations between the intake of total fat, saturated fat,
MUFA, PUFA, linolenic acid and linoleic acid with the risk of
colon or rectal cancer are presented in Table II. Incidence RR
and 95% CI for colon and rectal cancer are adjusted for age and
sex and for age, sex, smoking, QI, energy intake and family
history of CRC. The age--sex adjusted RR and the multivariate
RR were similar. Frequent consumption of total fat, saturated
fat, MUFA, PUFA, linolenic acid and linoleic acid were all not
associated with the risk of colon or rectal cancer (Table II).
Associations of total fat, saturated fat, MUFA, PUFA, lino-
lenic and linoleic acid with wild-type K-ras tumours and
mutated K-ras tumours in the colon or rectum are presented
in Table III. Results will first be discussed for wild-type K-ras
tumours. No clear associations were observed for high intakes
of total fat, saturated fat, MUFA, PUFA, linolenic acid and
linoleic acid and the risk of colon and rectal cancer with a wild-
type K-ras gene. With regard to the colon mutated K-ras
tumours, positive associations were observed for high intakes
of PUFA (RR for highest versus lowest quartile of intake 2.09,
95% CI 1.25--3.49, Ptrend 0.002) and specifically linoleic acid
(RR for highest versus lowest quartile of intake 2.19, 95%CI
1.30--3.67, Ptrend 0.002), but not linolenic acid. These positive
associations were also observed for 1 SD of increase of intake
(Table III). No significant associations were observed for
rectal mutated K-ras tumours and for highest versus lowest
intakes of total fat, saturated fat, MUFA and linolenic acid and
colon and rectal cancer with mutated K-ras tumours.
Subgroup analyses were performed to evaluate the associa-
tions between total fat, saturated fat, MUFA, PUFA, linolenic
acid and linoleic acid intakes and specific types of K-ras point
mutations (G4A transitions and G4T or G4C transversions)
Table I. Nutrient intake (mean  SD) and other characteristics of the study population at baseline
Subcohort Colon cancer P-valuea Rectal cancer P-valuea
K-rasÿ K-ras K-rasÿ K-ras
n 2948 297 151 93 67
Sex (% men) 48.2 51.5 58.9 0.14 72.0 55.2 0.03
Age (years) 61.3  4.2 62.7  4.0 63.8  4.1 0.005 62.6  4.1 62.2  4.0 0.55
Fat variables
Total fat (g/day) 83.8  15.8 84.3  15.4 86.7  14.8 0.12 86.7  15.3 86.0  14.2 0.76
Saturated fat (g/day) 33.2  7.5 33.5  6.9 33.6  6.7 0.89 34.1  6.8 34.3  6.9 0.87
MUFA (g/day) 31.4  7.0 31.7  6.5 32.1  6.9 0.54 32.2  6.6 32.5  5.6 0.80
PUFA (g/day) 17.3  7.5 17.2  7.3 19.3  7.6 0.006 18.5  8.9 17.5  8.2 0.46
Linolenic acid (g/day) 1.3  0.6 1.2  0.5 1.3  0.6 0.18 1.2  0.6 1.3  0.5 0.41
Linoleic acid (g/day) 16.0  7.5 16.1  7.3 18.0  7.7 0.009 17.4  8.9 16.2  8.3 0.41
Other dietary factors
Fibre (g/day) 27.0  8.2 26.7  7.6 27.7  8.8 0.02 27.8  8.0 27.6  7.8 0.87
Alcohol (g/day)b 10.1  14.1 11.0  15.4 10.8  14.2 0.59 13.8  17.6 11.2  12.2 0.30
Fruit (g/day) 177.0  118.0 172.7  123.7 176.9  122.2 0.73 184.3  145.8 180.7  129.9 0.87
Vegetable (g/day) 193.8  82.2 183.3  78.2 198.0  87.0 0.07 192.9  72.4 188.0  110.6 0.74
Energy (kcal/day) 1919.1  517.1 1916.5  494.4 1902.7  472.9 0.78 2027.3  517.4 1997.0  449.1 0.70
Other characteristics
QI (kg/m2) 25.1  3.1 25.5  3.2 25.8  3.3 0.42 24.9  2.8 25.5  2.9 0.20
Family history of CRC (% yes) 5.7 13.5 9.3 0.20 9.7 11.9 0.66
Smoker (%)
Never 36.9 36.7 37.1 25.8 34.3
Ex-smoker 35.2 43.1 46.4 41.9 43.3
Current smoker 27.8 20.2 16.6 0.62 32.3 22.4 0.31
Physical activity (%)c
530 min/day 20.1 19.7 20.3 18.5 22.7
30--60 min/day 32.2 33.7 32.4 27.2 27.3
60--90 min/day 31.1 29.6 29.1 32.6 34.8
490 min/day 15.4 17.0 18.2 0.98 21.7 15.2 0.73
aComparing cases with at least one K-ras mutation to cases without a K-ras mutation.
bFor alcohol intake the mean levels in the subcohort are based on 2862 subjects.
cFor physical activity the mean levels in the subcohort are based on 2915 subjects.
Adjusted for energy by the residual method (29).
Monounsaturated fat.
Polyunsaturated fat.
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Table II. Incidence RR and 95% CI for colon and rectal cancer patients (448 colon and 160 rectal cancer cases) according to the intake of total fat and
specific fatty acids
Exposure Quartile of intake RR (95% CI) for
1 SD increase
in intake#
Q1a Q2 Q3 Q4 P for trend
Total fat
Median intake (g/day)
Men 78.1 90.3 98.5 109.1
Women 63.0 71.5 77.6 85.3
Colon cases/rectal cases/person-years 113/43/3657 126/42/3675 95/34/3741 114/40/3664
RR (95% CI)b
Colon 1.00 1.09 (0.82--1.43) 0.80 (0.60--1.08) 0.99 (0.74--1.32) 0.49 1.02 (0.90--1.15)
Rectum 1.00 0.96 (0.62--1.49) 0.75 (0.47--1.20) 0.92 (0.59--1.44) 0.52 0.94 (0.78--1.13)
RR (95% CI)c
Colon 1.00 1.09 (0.82--1.44) 0.74 (0.55--1.01) 0.95 (0.71--1.27) 0.28 1.00 (0.88--1.13)
Rectum 1.00 0.89 (0.56--1.39) 0.74 (0.46--1.19) 0.86 (0.55--1.36) 0.41 0.91 (0.76--1.09)
Saturated fat
Median intake (g/day)
Men 28.9 33.7 38.5 45.8
Women 23.9 27.8 31.0 36.6
Colon cases/rectal cases/person-years 101/43/3645 123/35/3703 119/46/3709 105/36/3679
RR (95% CI)b
Colon 1.00 1.20 (0.90--1.59) 1.14 (0.85--1.51) 0.97 (0.72--1.30) 0.72 0.98 (0.89--1.09)
Rectum 1.00 0.80 (0.50--1.26) 1.04 (0.67--1.59) 0.80 (0.51--1.26) 0.58 0.97 (0.83--1.15)
RR (95% CI)c
Colon 1.00 1.19 (0.88--1.60) 1.10 (0.82--1.49) 0.93 (0.69--1.26) 0.51 0.97 (0.87--1.08)
Rectum 1.00 0.79 (0.49--1.28) 1.02 (0.65--1.59) 0.73 (0.46--1.17) 0.37 0.95 (0.80--1.12)
MUFA
Median intake (g/day)
Men 28.2 33.2 36.9 42.5
Women 22.4 26.1 28.9 33.0
Colon cases/rectal cases/person-years 101/45/3660 124/34/3650 119/41/3714 104/40/3713
RR (95% CI)b
Colon 1.00 1.23 (0.92--1.63) 1.17 (0.88--1.56) 1.03 (0.76--1.37) 0.97 1.00 (0.89--1.11)
Rectum 1.00 0.76 (0.48--1.21) 0.91 (0.59--1.41) 0.89 (0.57--1.38) 0.77 0.93 (0.79--1.10)
RR (95% CI)c
Colon 1.00 1.19 (0.89--1.60) 1.12 (0.82--1.51) 0.98 (0.73--1.33) 0.77 0.99 (0.88--1.12)
Rectum 1.00 0.70 (0.44--1.13) 0.91 (0.57--1.44) 0.87 (0.56--1.37) 0.80 0.93 (0.78--1.11)
PUFA
Median intake (g/day)
Men 11.6 16.0 21.0 29.1
Women 8.8 12.4 16.2 22.5
Colon cases/rectal cases/person-years 95/47/3656 124/33/3683 113/39/3726 116/41/3667
RR (95% CI)b
Colon 1.00 1.35 (1.01--1.81) 1.23 (0.92--1.66) 1.24 (0.92--1.66) 0.26 1.05 (0.96--1.16)
Rectum 1.00 0.71 (0.45--1.13) 0.84 (0.54--1.30) 0.87 (0.56--1.34) 0.68 1.00 (0.84--1.19)
RR (95% CI)c
Colon 1.00 1.38 (1.02--1.86) 1.24 (0.91--1.68) 1.21 (0.89--1.64) 0.37 1.03 (0.94--1.14)
Rectum 1.00 0.74 (0.46--1.19) 0.86 (0.55--1.34) 0.83 (0.53--1.29) 0.54 0.98 (0.83--1.16)
Linolenic acid
Median intake (g/day)
Men 0.8 1.2 1.5 2.0
Women 0.6 0.9 1.2 1.6
Colon cases/rectal cases/person-years 108/44/3642 108/40/3684 124/36/3657 108/40/3750
RR (95% CI)b
Colon 1.00 0.97 (0.73--1.30) 1.15 (0.87--1.52) 1.01 (0.76--1.35) 0.65 0.99 (0.90--1.09)
Rectum 1.00 0.89 (0.57--1.38) 0.81 (0.51--1.28) 0.90 (0.58--1.41) 0.59 0.94 (0.79--1.11)
RR (95% CI)c
Colon 1.00 0.95 (0.70--1.30) 1.10 (0.82--1.47) 1.01 (0.75--1.36) 0.70 0.98 (0.89--1.09)
Rectum 1.00 0.91 (0.57--1.47) 0.87 (0.55--1.38) 0.91 (0.58--1.44) 0.67 0.95 (0.80--1.12)
Linoleic acid
Median intake (g/day)
Men 10.0 14.8 19.5 27.9
Women 7.4 11.2 15.0 21.2
Colon cases/rectal cases/person-years 91/41/3658 126/40/3700 113/35/3699 118/44/3676
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in colon and rectal tumours (Table IV). High intake of PUFA
and specifically linoleic acid showed positive associations
with colon tumours harbouring G4A transitions (RR for high-
est versus lowest quartile of intake 1.95, 95% CI 1.01--3.77 and
RR 1.80, 95% CI 0.92--3.51, respectively) or G4T or G4C
transversions (RR 2.17, 95% CI 0.98--4.80 and RR 2.69, 95%
CI 1.19--6.08, respectively). These positive associations were
also observed for 1 SD of increase of intake (Table IV). There
were no associations found between PUFA and linoleic acid
intake and rectal tumours with G4A transitions or G4T or
G4C transversions. In addition, no significant associations
were observed between highest versus lowest quartile of intake
of total fat, saturated fat, MUFA and linolenic acid and the risk
of G4A transitions or G4T or G4C transversions in colon
and rectal tumours.
Discussion
In this study, no associations were observed between intakes of
specific fats or fatty acids and overall colon and rectal cancer
risk. However, associations were observed when taking into
account the presence or absence of specific point mutations in
the K-ras gene of colon and rectal cancer patients. No signific-
ant associations were observed for total fat, saturated fat, and
MUFA intakes and the risk of colon and rectal tumours without
or with a K-ras mutation. In contrast, positive associations
were observed for high intake of PUFA, specifically linoleic
acid but not linolenic acid, and the risk of colon tumours
harbouring K-ras oncogene mutations. Subgroup analyses of
specific point mutations in the K-ras gene revealed that these
positive associations were observed for G4A transitions and
G4T and G4C transversions.
This cohort study on fat and specific fatty acids intake in
relation to specific K-ras mutations in colon and rectal cancer
is, to our knowledge, the only prospective study performed to
date. One large case-control study with colon cancer patients
(11), two case-control studies of limited size among colon
(13), and colon and rectal cancer patients (12) and one cross-
sectional case--case study with colorectal adenoma patients
(14) have been conducted previously. The prospective design of
the current study and high completeness of follow-up of cancer
incidence and subcohort, make information and selection bias
unlikely. In addition, as a result of the exclusion of the first
2.3 years of follow-up, the chance of information bias due to
potential pre-clinical colorectal cancer is minimal. Finally,
tumour tissue was available for 84% of the eligible cases
(776 out of 929) and there were no significant differences in
fat intake levels nor in clinicopathological characteristics of
the tumour (Dukes' stage and differentiation grade) of these
patients compared with the CRC patients with a known K-ras
mutation status of their tumour (data not shown). Therefore,
selection bias due to loss to follow-up is unlikely.
In general, the validation of the fat intake variables was
satisfactory (see Materials and methods section and ref. 27).
Although total fat intake and energy intake may have been
underestimated as compared with the 9-day record method in
the validation study (27) and, in addition, there is inevitably a
certain degree of misclassification of fat intake variables, it is
not expected that this is differential with respect to the K-ras
mutation status of the tumour. Therefore, the associations
observed in this study are probably attenuated. In other epide-
miological studies similar inaccuracies occur in the measure-
ment of fat intake since similar methods of intake assessment
were employed (11,12,14).
One of the hypotheses for the association between fat intake
and colorectal cancer is that meat consumption instead of fat
intake determines the increased risk. We also investigated
meat consumption as a potential risk factor for K-ras mutations
in colon and rectal cancer, and total fresh meat was not asso-
ciated with risk. Therefore, we did not additionally adjust for
this potential confounder in these analyses.
In the current study, a high intake of total and saturated fats
was not associated with overall colon or rectal cancer risk and
with K-ras mutation status and these findings are supported by
others (11,13,14). Bautista et al. (12) observed an inverse
association between a high intake of total fat and colorectal
tumours with a K-ras wild-type gene (odds ratio for highest
versus lowest tertile of intake 0.47, 95% CI 0.22--0.99). How-
ever, the results were based on only 108 colorectal cancer
cases in a population-based case-control setting, and therefore
estimates of associations must be interpreted with caution.
Animal studies indicated an inverse association of high
MUFA intake, derived mainly from oleic acid with colorectal
cancer risk (32,33). However, in epidemiological studies, no
clear associations were observed with colorectal cancer risk
(34--36). Regarding the K-ras mutation status, no associations
Table II. continued
Exposure Quartile of intake RR (95% CI) for
1 SD increase
in intake#
Q1a Q2 Q3 Q4 P for trend
RR (95% CI)b
Colon 1.00 1.44 (1.07--1.92) 1.29 (0.96--1.73) 1.30 (0.97--1.75) 0.17 1.07 (0.97--1.18)
Rectum 1.00 0.98 (0.63--1.54) 0.86 (0.54--1.37) 1.06 (0.68--1.64) 0.96 1.02 (0.86--1.21)
RR (95% CI)c
Colon 1.00 1.49 (1.10--2.02) 1.32 (0.97--1.80) 1.31 (0.97--1.77) 0.19 1.06 (0.96--1.17)
Rectum 1.00 1.03 (0.65--1.64) 0.90 (0.56--1.45) 1.03 (0.66--1.62) 0.96 1.00 (0.84--1.18)
aReference category of quartiles of intake.
bRelative risk adjusted for age and sex.
cRelative risk adjusted for age, sex, QI, smoking, energy intake and family history of CRC.
Adjusted for energy by the residual method (29).
Monounsaturated fat.
Polyunsaturated fat.
#See for 1 SD of increase Table I.
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Table III. Adjusted RRa and 95% CI for colon and rectal cancer patients with wild type K-ras gene and with mutated K-ras oncogene according to the
intake of total fat and specific fatty acids
Exposure Quartile of intake RR (95% CI) for
1 SD increase
in intake#Q1b Q2 Q3 Q4 P for trend
Total fat
Cases
Colon K-rasÿ/K-ras 75/35 81/44 57/32 77/33
K-rasÿ/K-ras rectum 25/18 26/13 21/12 16/22
RRK-rasÿ (95% CI)
Colon 1.00 1.04 (0.74--1.45) 0.71 (0.49--1.02) 0.99 (0.70--1.38) 0.48 0.98 (0.84--1.13)
Rectum 1.00 1.00 (0.57--1.76) 0.80 (0.44--1.47) 0.63 (0.33--1.20) 0.11 0.81 (0.64--1.02)
RRK-ras (95% CI)
Colon 1.00 1.19 (0.75--1.90) 0.82 (0.49--1.36) 0.88 (0.54--1.44) 0.32 1.03 (0.84--1.26)
Rectum 1.00 0.72 (0.35--1.51) 0.65 (0.31--1.37) 1.18 (0.63--2.23) 0.65 1.07 (0.81--1.41)
Saturated fat
Cases
Colon K-rasÿ/K-ras 60/39 86/34 76/39 68/32
K-rasÿ/K-ras rectum 25/18 21/13 26/18 17/16
RRK-rasÿ (95% CI)
Colon 1.00 1.42 (0.99--2.02) 1.22 (0.84--1.75) 1.06 (0.74--1.54) 0.96 1.01 (0.89--1.15)
Rectum 1.00 0.82 (0.45--1.52) 1.02 (0.57--1.80) 0.64 (0.34--1.21) 0.28 0.86 (0.70--1.06)
RRK-ras (95% CI)
Colon 1.00 0.85 (0.52--1.38) 0.92 (0.58--1.48) 0.73 (0.45--1.18) 0.26 0.90 (0.75--1.07)
Rectum 1.00 0.75 (0.35--1.59) 1.02 (0.52--2.01) 0.86 (0.43--1.72) 0.89 1.08 (0.85--1.39)
MUFA
Cases
Colon K-rasÿ/K-ras 61/37 81/41 73/40 75/26
K-rasÿ/K-ras rectum 29/15 19/12 21/19 20/19
RRK-rasÿ (95% CI)
Colon 1.00 1.27 (0.89--1.82) 1.16 (0.80--1.68) 1.18 (0.82--1.68) 0.53 1.01 (0.88--1.17)
Rectum 1.00 0.64 (0.35--1.17) 0.71 (0.39--1.28) 0.69 (0.38--1.24) 0.27 0.82 (0.64--1.06)
RRK-ras (95% CI)
Colon 1.00 1.06 (0.66--1.70) 1.04 (0.64--1.69) 0.67 (0.40--1.13) 0.14 0.94 (0.77--1.16)
Rectum 1.00 0.81 (0.38--1.76) 1.31 (0.64--2.68) 1.22 (0.61--2.44) 0.34 1.10 (0.89--1.37)
PUFA
Cases
Colon K-rasÿ/K-ras 68/23 87/31 72/41 63/49
K-rasÿ/K-ras rectum 24/21 18/14 25/14 22/16
RRK-rasÿ (95% CI)
Colon 1.00 1.36 (1.00--1.91) 1.05 (0.73--1.49) 0.91 (0.63--1.31) 0.32 0.94 (0.83--1.07)
Rectum 1.00 0.76 (0.41--1.43) 1.03 (0.58--1.82) 0.89 (0.49--1.62) 0.96 0.97 (0.78--1.21)
RRK-ras (95% CI)
Colon 1.00 1.44 (0.82--2.52) 1.83 (1.08--3.11) 2.09 (1.25--3.49) 0.002 1.21 (1.05--1.41)
Rectum 1.00 0.72 (0.36--1.45) 0.67 (0.33--1.34) 0.75 (0.39--1.44) 0.38 0.99 (0.77--1.27)
Linolenic acid
Cases
Colon K-rasÿ/K-ras 69/38 71/33 79/38 71/35
K-rasÿ/K-ras rectum 30/12 21/17 18/18 20/18
RRK-rasÿ (95% CI)
Colon 1.00 1.02 (0.70--1.46) 1.16 (0.82--1.64) 1.05 (0.74--1.49) 0.63 0.95 (0.85--1.08)
Rectum 1.00 0.65 (0.36--1.18) 0.57 (0.32--1.04) 0.66 (0.37--1.17) 0.14 0.86 (0.70--1.11)
RRK-ras (95% CI)
Colon 1.00 0.84 (0.50--1.41) 1.00 (0.62--1.60) 0.95 (0.59--1.55) 0.97 1.04 (0.88--1.23)
Rectum 1.00 1.57 (0.71--3.50) 1.62 (0.76--3.45) 1.54 (0.73--3.25) 0.27 1.07 (0.88--1.29)
Linoleic acid
Cases
Colon K-rasÿ/K-ras 64/22 89/33 72/40 65/49
K-rasÿ/K-ras rectum 20/19 26/13 20/15 23/18
RRK-rasÿ (95% CI)
Colon 1.00 1.46 (1.03--2.06) 1.14 (0.79--1.63) 1.01 (0.70--1.45) 0.63 0.97 (0.86--1.10)
Rectum 1.00 1.32 (0.73--2.39) 0.99 (0.53--1.86) 1.12 (0.61--2.07) 0.97 0.99 (0.80--1.23)
RRK-ras (95% CI)
Colon 1.00 1.60 (0.92--2.80) 1.87 (1.09--3.22) 2.19 (1.30--3.67) 0.002 1.22 (1.05--1.42)
Rectum 1.00 0.72 (0.34--1.51) 0.81 (0.40--1.63) 0.93 (0.48--1.79) 0.91 1.00 (0.77--1.29)
aMultivariate adjusted RR for age, sex, QI, smoking, energy intake and family history of CRC and their 95% CI.
bReference category of quartiles of intake.
Adjusted for energy by the residual method (29).
Monounsaturated fat.
Polyunsaturated fat.
#See for 1 SD of increase Table I.
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Table IV. Adjusted RRa and 95% CI for colon and rectal cancer patients with G4A transitions or with G4T or G4C transversions in the K-ras oncogene
according to the intake of total fat and specific fatty acids
Exposure Quartile of intake RR (95% CI) for
1 SD increase
in intake#Q1b Q2 Q3 Q4 P for trend
Total fat
Cases
G4A/ G4T, G4C
Colon 20/15 23/20 17/12 22/9
Rectum 12/7 6/7 6/7 9/11
RRG4A (95% CI)
Colon 1.00 1.11 (0.60--2.07) 0.78 (0.40--1.52) 1.02 (0.54--1.90) 0.79 1.09 (0.82--1.44)
Rectum 1.00 0.45 (0.17--1.22) 0.43 (0.16--1.19) 0.74 (0.31--1.79) 0.50 0.87 (0.57--1.32)
RRG4T,G4C (95% CI)
Colon 1.00 1.26 (0.64--2.48) 0.72 (0.33--1.56) 0.57 (0.25--1.30) 0.07 0.90 (0.69--1.17)
Rectum 1.00 1.09 (0.37--3.20) 1.07 (0.37--3.11) 1.50 (0.58--3.89) 0.42 1.17 (0.84--1.63)
Saturated fat
Cases
G4A/ G4T, G4C
Colon 23/14 16/17 23/15 20/10
Rectum 9/10 5/8 13/3 6/11
RRG4A (95% CI)
Colon 1.00 0.69 (0.36--1.34) 0.95 (0.52--1.74) 0.76 (0.41--1.42) 0.60 0.95 (0.75--1.19)
Rectum 1.00 0.51 (0.17--1.55) 1.31 (0.55--3.10) 0.64 (0.23--1.84) 0.88 1.01 (0.70--1.45)
RRG4T;G4C (95% CI)
Colon 1.00 1.19 (0.57--2.47) 1.00 (0.47--2.10) 0.63 (0.28--1.43) 0.21 0.79 (0.62--1.01)
Rectum 1.00 0.91 (0.34--2.44) 0.33 (0.08--1.25) 1.07 (0.45--2.55) 0.84 1.15 (0.80--1.64)
MUFA
Cases
G4A/G4T, G4C
Colon 19/17 21/18 25/13 17/8
Rectum 10/4 6/7 7/13 10/8
RRG4A (95% CI)
Colon 1.00 1.09 (0.57--2.09) 1.34 (0.70--2.56) 0.84 (0.43--1.66) 0.78 1.05 (0.80--1.39)
Rectum 1.00 0.53 (0.19--1.46) 0.59 (0.22--1.66) 0.96 (0.40--2.33) 0.99 1.06 (0.71--1.60)
RRG4T;G4C (95% CI)
Colon 1.00 1.01 (0.51--1.98) 0.72 (0.34--1.51) 0.46 (0.20--1.07) 0.04 0.78 (0.60--1.02)
Rectum 1.00 2.00 (0.57--7.07) 4.00 (1.25--12.81) 1.93 (0.57--6.56) 0.12 1.12 (0.91--1.37)
PUFA
Cases
G4A/G4T, G4C
Colon 14/9 18/13 23/14 27/20
Rectum 11/10 6/9 11/4 5/9
RRG4A (95% CI)
Colon 1.00 1.44 (0.71--2.94) 1.76 (0.89--3.49) 1.95 (1.01--3.77) 0.04 1.18 (0.97--1.42)
Rectum 1.00 0.51 (0.18--1.43) 0.86 (0.35--2.11) 0.42 (0.14--1.20) 0.21 0.80 (0.57--1.12)
RRG4T;G4C (95% CI)
Colon 1.00 1.51 (0.64--3.60) 1.57 (0.67--3.70) 2.17 (0.98--4.80) 0.06 1.24 (0.98--1.57)
Rectum 1.00 1.10 (0.44--2.74) 0.45 (0.14--1.46) 0.94 (0.38--2.30) 0.59 1.02 (0.72--1.45)
Linolenic acid
Cases
G4A/G4T, G4C
Colon 24/14 13/18 24/14 21/10
Rectum 6/6 8/9 9/11 11/6
RRG4A (95% CI)
Colon 1.00 0.54 (0.26--1.11) 1.02 (0.57--1.85) 0.91 (0.49--1.70) 0.79 1.04 (0.83--1.29)
Rectum 1.00 1.04 (0.33--3.28) 1.39 (0.47--4.04) 1.75 (0.62--4.95) 0.22 1.21 (0.92--1.59)
RRG4T;G4C (95% CI)
Colon 1.00 1.26 (0.57--2.80) 1.00 (0.47--2.14) 0.75 (0.32--1.72) 0.38 0.95 (0.73--1.25)
Rectum 1.00 1.91 (0.64--5.66) 2.21 (0.81--6.03) 1.09 (0.35--3.38) 0.75 0.92 (0.71--1.20)
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were observed for high intake of MUFA and the risk of colon
and rectal cancer in the current study. This is in line with
Slattery's observation (11). However, Bautista et al. (12)
observed that a high intake of MUFA was inversely associated
with the risk of having a wild-type K-ras gene. This study was
conducted in Spain where the main source of oleic acid is olive
oil. This is not the case for the current cohort and could be an
explanation for the different findings. The association was not
reported in the other studies (13,14).
To our best knowledge, this is the first study reporting on
specific PUFAs in relation to K-ras mutation status. Overall
PUFA intake was studied by Slattery et al. (11) and Bautista
et al. (12) and no associations were observed with K-ras
mutation status.
In the current study, no clear associations were observed
between the high intake of linolenic acid as the main source
of v-3 PUFAs, and the risk of colon or rectal cancer with or
without specific point mutations in the K-ras gene. Epidemio-
logical, clinical and experimental data indicate a protective
effect of fish oil-derived v-3 PUFAs on overall colon cancer
(35,37--44). Collett et al. (37) demonstrated that the major v-3
PUFA constituent of fish oil, docosahexaenoic acid reduces
the Ras protein localization to the plasma membrane without
affecting post-translational lipidation and lowers the GTP-
binding of the Ras protein in mouse colonocytes treated with
azoxymethane (colon carcinogen). These findings were corrob-
orated by in vivo studies (45). Another hypothesis is that the
tumour-promoting activity of v-6 PUFA was abrogated by
competitive inhibition of v-3 PUFA from the metabolism of
arachidonic acid and therefore reducing MDA levels and sub-
sequently M1G4T and M1G4C transversions (38). Summar-
ized, v-3 PUFAs may exert their effect through inhibition of
the Ras protein activity and not by generating functional
aberrations in the exon 1 fragment of the K-ras oncogene.
This could explain the lack of association between linolenic
acid and K-ras mutation status of colon or rectal tumours in
this study.
In the current study, no significant association was observed
for linoleic acid, as the main source of v-6 PUFAs intake, and
the overall risk of colon or rectal cancer. This is in line with
most epidemiological evidence up to date (46). However, a
positive effect was found between high intake of linoleic acid
and colon tumours harbouring K-ras gene mutations. Sub-
group analyses of specific point mutations in the K-ras gene
revealed that colon tumours harbouring G4A transitions or
G4T or G4C transversions are positively associated with
high linoleic acid intake. These associations are in line with
the biological evidence (16,18) and are possibly the result of an
increased formation of G-adducts resulting in G4A trans-
itions or G4T or G4C transversions. Increased intake of v-
6 PUFAs enhance tumorigenesis in experimental animals and
in vitro systems by several mechanisms (47). The conjugated
double bonds in PUFAs are highly sensitive to lipid peroxida-
tion, and may generate fatty acid hydroperoxides. These
hydroperoxides will be reduced by glutathione peroxidase
to non-reactive fatty acid alcohols or may react with metal
ions to yield alkoxyl radicals. The fatty acid alcohols do not lead
to DNA damage and will not be discussed further. However,
alkoxyl radicals are reduced to aldehydes, with 2,3-epoxy-4-
hydroxynonanal (4-HNE) and MDA as the most prominent
forms. The bifunctional alkylating agent 4-HNE can react
with DNA to yield etheno and other base adducts which are
thought to promote the carcinogenic process. Etheno-dG
induces mainly transitions to A and transversions to T in
bacteria (16,33,48,49) and etheno-dC induces transitions to T
in the kidneys of monkeys (50). MDA is a major genotoxic
carbonyl compound, which is also a by-product of the arachi-
donic acid metabolism in the synthesis of prostaglandins.
MDA is mutagenic in bacterial and mammalian cells, and
carcinogenic in rats (18). MDA reacts with DNA to form
adducts, predominantly with deoxyguanosine to generate
M1G (15). The most common mutations in progeny molecules
are G4T transversions and G4A transitions, with a minor
contribution by G4C transversions (16,18,19). In the current
study, the associations with G4A transitions, G4T and G4C
transversions in the K-ras oncogene were only observed for
colon cancer patients and not for rectal cancer patients. The
reason for this apparent difference in the aetiology remains
unclear. In addition, the observed significant association found
for colon cancer could be a result of a type I error due to the
Table IV. continued
Exposure Quartile of intake RR (95% CI) for
1 SD increase
in intake#Q1b Q2 Q3 Q4 P for trend
Linoleic acid
Cases
G4A/G4T, G4C
Colon 14/8 19/14 24/12 25/22
Rectum 11/10 6/7 10/6 7/9
RRG4A (95% CI)
Colon 1.00 1.51 (0.75--3.07) 1.85 (0.93--3.66) 1.80 (0.92--3.51) 0.06 1.19 (0.98--1.44)
Rectum 1.00 0.56 (0.19--1.60) 0.89 (0.35--2.26) 0.65 (0.24--1.74) 0.59 0.81 (0.57--1.15)
RRG4T ;G4C (95% CI)
Colon 1.00 1.83 (0.76--4.40) 1.52 (0.61--3.77) 2.69 (1.19--6.08) 0.03 1.27 (1.00--1.61)
Rectum 1.00 0.83 (0.31--2.27) 0.70 (0.25--1.94) 0.94 (0.38--2.31) 0.83 1.06 (0.74--1.53)
aMultivariate adjusted RR for age, sex, QI, smoking, energy intake and family history of CRC and their 95% CI.
bReference category of quartiles of intake.
Adjusted for energy by the residual method (29).
Monounsaturated fat.
Polyunsaturated fat.
#See for 1 SD of increase Table I.
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numerous associations analysed in this study. Although the
studied associations were mainly hypotheses-driven, caution
is warranted in interpreting these results and further investiga-
tions are needed.
Our results suggest that PUFA, and in particular linoleic
acid, is an important dietary risk factor for colon tumours
with K-ras mutations possibly by generating G4A transitions
or G4T or G4C transversions in the exon 1 fragment of the
K-ras oncogene. This implies that, for some dietary exposures
like polyunsaturated fat intake, it is meaningful to account for
somatic mutations in the K-ras oncogene in the aetiology of
colon and rectal cancer.
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